Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)

2021-02-26T19:12:02-08:00September 27th, 2018|2018 Press Releases, Press Releases|